NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) said that the U.S. Food
and Drug Administration approved Darzalex Faspro (daratumumab and
hyaluronidase-fihj) in combination with bortezomib, lenalidomide and
dexamethasone (D-VRd) for induction and consolidation in patients with newly
diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell
transplant (ASCT).

This approval is supported by data from the Phase 3 PERSEUS study evaluating
Darzalex Faspro in a regimen that included D-VRd induction and consolidation
therapy compared to bortezomib, lenalidomide and dexamethasone (VRd) during
induction and consolidation in patients with NDMM eligible for ASC.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX